Vayarin® has been studied in a double-blind, placebo controlled, randomized clinical study that was published in a peer-reviewed journal publication, in addition to several retrospective studies.
MEDICAL FOOD: CLINICAL STUDY DESIGN
VAYARIN® WAS CLINICALLY SHOWN TO REDUCE ADHD BEHAVIORS, ESPECIALLY IN CHILDRENT WITH MORE PRONOUNCED EMOTIONAL DYSREGULATION
Results with the subgroup: Children were included in this subgroup if they had an abnormal baseline score (<62) in at least two out of the following CRS T subscales: Oppositional, Hyperactivity, ADHD-index, or Global: Emotional liability. #p ≤ 0.15 *p < 0.05 Based on analysis of covariance controlled for gender and age.
Manor, I., et al., Eur Psychiatry. 2012; 27(5): p. 335-42
VAYARIN® WAS CLINICALLY SHOWN TO IMPROVE QUALITY OF LIFE
Based on Student’s t-test. Similar results were observed within subset of hyperactive-impulsive children.
Manor, I., et al., Eur. Psychiatry. 2012. 25(5): p. 335-42
PROVEN SAFE IN CHILDREN
- Clinically shown to be safe & well tolerated in children
- No known contraindications have been reported with ADHD medications
Our patented PS-Omega-3 structure was studied in animal model and shown to be superior in increasing the bioavailability of Omega-3 in brain tissue, compared to control and common Omega-3 products: fish oil, phosphatidylserine (soy-PS), and soy-PS added to fish oil.
PS-OMEGA-3 RESULTED IN HIGHER BIOAVAILABILITY TO THE BRAIN IN ANIMAL MODEL
A significant increase of 42% in Omega-3 bioavailability in the brain versus control
*p < 0.05 compared to control, based on one-way ANOVA
Vaisman N., et al., Prog Neuropsychopharmacol Biol Psychiatry 2009;33:952-959